Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety of the switch from Efavirenz / emtricitabine / tenofovir difumarate taken once daily or alternate days to Bictegravir / emtricitabine / tenofovir alafenamide in HIV + virologically suppressed patients

Next Previous
X
Search
Trial Profile

Efficacy and safety of the switch from Efavirenz / emtricitabine / tenofovir difumarate taken once daily or alternate days to Bictegravir / emtricitabine / tenofovir alafenamide in HIV + virologically suppressed patients

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 29 Dec 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bictegravir/emtricitabine/tenofovir alafenamide (Primary)
  • Indications HIV infections
  • Focus Therapeutic Use
  • Acronyms EBONY

    • Most Recent Events

    • 30 Oct 2021 Results(N=214) assessing weight gain after switching from EFV/FTC/TDF to BIC/FTC/TAF in patients from the EBONY study presented at the 18th European AIDS Conference
    • 30 Oct 2021 Results (n=126) assessing whether a switch strategy from EFV/F/TDF to B/F/TAF may improve psychiatric symptoms and sleep quality and whether it has an impact on neurocognition, presented at the 18th European AIDS Conference.
    • 08 Sep 2021 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top